RayKnowChina Research Map
Shortlist

Not yet recruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteSecond Hospital of Dalian Medical University大连医科大学附属第二医院DalianHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06324994, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Suffering from ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia [including QTc ≥ 450ms (male), QTc ≥ 470ms (female)], and ≥ grade 2 congestive heart failure [NYHA classification];

    Exclusion criterion 13

  3. Women with a possibility of pregnancy must undergo a serum pregnancy test within 7 days before the first medication, and the result is negative. They are willing to Intended to use efficient methods of contraception during the trial period and within 1 year after the last administration of the investigational drug. For male subjects whose partners are women of childbearing age, they should undergo surgical sterilization or agree to use high-efficiency contraception methods during the trial period and 1 year after the last administration of the trial drug;

    Inclusion criterion 18

    Patients who have received any targeted PI3K or BCL treatment before enrollment;

    Exclusion criterion 1

  4. The Eastern Oncology Collaborative Group (ECOG) scored 0-2 on physical fitness status;

    Inclusion criterion 3

  5. Hemoglobin (Hb) ≥ 80 g/L;

    Inclusion criterion 9

    Neutrophils (ANC) ≥ 1.0 × 109/L;

    Inclusion criterion 10

    Platelet count (PLT) ≥ 75 × 109/L;

    Inclusion criterion 11

    TBIL<1.5 × Upper limit of normal range (ULN);

    Inclusion criterion 12

    Glutamate alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN;

    Inclusion criterion 13

    Serum creatinine (Cr) ≤ 1.25 × ULN or endogenous creatinine clearance rate ≥ 60 mL/min (Cockcroft Gault formula);

    Inclusion criterion 14

    International normalized ratio (INR) ≤ 1.5 × ULN;

    Inclusion criterion 15

    Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;

    Inclusion criterion 16

  6. There is at least one measurable lesion: the longest diameter (LDi) of lymph node lesions is ≥ 1.5 cm, or the LDi of extralymph node lesions is ≥ 1 cm, or splenomegaly, or bone marrow involvement with or without malignant lymphocytosis;

    Inclusion criterion 5

  7. History of other primary invasive malignant tumors that have not been relieved or have not been relieved for more than 3 years;

    Exclusion criterion 2

    Have a history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;

    Exclusion criterion 22

  8. Pregnant or lactating women;

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06324994, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥ 18 years old;
  • Mother cell type mantle cell lymphoma (BV-MCL) confirmed by histopathological and immunophenotypic analysis;
  • The Eastern Oncology Collaborative Group (ECOG) scored 0-2 on physical fitness status;
  • Expected lifespan ≥ 3 months
  • There is at least one measurable lesion: the longest diameter (LDi) of lymph node lesions is ≥ 1.5 cm, or the LDi of extralymph node lesions is ≥ 1 cm, or splenomegaly, or bone marrow involvement with or without malignant lymphocytosis;
  • Have not received treatment with PI3K inhibitors and BCL-2 inhibitors in the past; Having sufficient bone marrow and organ functions;
  • Having sufficient bone marrow and organ functions;
  • All screening period laboratory tests must be conducted according to the requirements of the plan, and must be conducted within 7 days before enrollment. The values of laboratory tests conducted for screening must meet the following criteria:

Blood routine examination (no blood transfusion, no use of granulocyte colony-stimulating factor (G-CSF), no medication correction within 14 days prior to screening):

  • Hemoglobin (Hb) ≥ 80 g/L;
  • Neutrophils (ANC) ≥ 1.0 × 109/L;
  • Platelet count (PLT) ≥ 75 × 109/L;

Biochemical examination:

  • TBIL<1.5 × Upper limit of normal range (ULN);
  • Glutamate alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN;
  • Serum creatinine (Cr) ≤ 1.25 × ULN or endogenous creatinine clearance rate ≥ 60 mL/min (Cockcroft Gault formula);

Coagulation function (unless the subject is receiving anticoagulant therapy and the coagulation parameters (PT/INR and APTT) are within the expected range of anticoagulant therapy at the time of screening):

  • International normalized ratio (INR) ≤ 1.5 × ULN;
  • Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;
  • Those who have not participated in clinical trials of other drugs within the 4 weeks prior to enrollment;
  • Women with a possibility of pregnancy must undergo a serum pregnancy test within 7 days before the first medication, and the result is negative. They are willing to Intended to use efficient methods of contraception during the trial period and within 1 year after the last administration of the investigational drug. For male subjects whose partners are women of childbearing age, they should undergo surgical sterilization or agree to use high-efficiency contraception methods during the trial period and 1 year after the last administration of the trial drug;
  • The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.

Exclusion Criteria:

  • Patients who have received any targeted PI3K or BCL treatment before enrollment;
  • History of other primary invasive malignant tumors that have not been relieved or have not been relieved for more than 3 years;
  • Those with involvement of the central nervous system (meninges or brain parenchyma);
  • Individuals who are known to have allergies to any medication in the study;
  • Participated in clinical trials of other drugs within 4 weeks prior to the start of the study;
  • Pregnant or lactating women;
  • Individuals with active infections, excluding fever related to tumor B symptoms;
  • Concomitant diseases and medical history:
  • There are multiple factors that affect oral medication, such as inability to swallow, chronic diarrhea, and intestinal obstruction
  • Individuals with a history of psychiatric drug abuse who are unable to quit or have mental disorders;
  • Subjects with any severe and/or uncontrolled diseases, including:
  • Poor blood pressure control (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg);
  • Suffering from ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia [including QTc ≥ 450ms (male), QTc ≥ 470ms (female)], and ≥ grade 2 congestive heart failure [NYHA classification];
  • Active interstitial pneumonia or other chronic lung diseases leading to severe impairment of lung function, defined as FEV1 and DLCOc<60% of normal predicted values;
  • Liver abnormalities;
  • Decompensated cirrhosis (Child Pugh liver function rating of B or C)
  • Known clinically significant history of liver disease. Including viral hepatitis, known carriers of hepatitis B virus (HBV) must exclude active HBV infection, i.e. HBV DNA positivity (>2500 copies/mL or>500 IU/mL, and above the upper limit of normal values); Known hepatitis C virus infection (HCV) and HCV RNA positivity (>1×103copies/mL). Note: hepatitis B HBsAg positive subjects who meet the inclusion conditions, whether their HBV DNA is measurable or not, need to continue antiviral treatment (nucleoside analogues are recommended) and regularly monitor HBV DNA; For subjects with positive HBcAb but negative HBsAg in hepatitis B, HBV DNA should be monitored regularly and preventive antiviral treatment should be recommended; Hepatitis C patients need to regularly monitor HCV RNA.
  • Renal failure requiring hemodialysis or peritoneal dialysis;
  • Subjects with uncontrolled pleural effusion, pericardial effusion, or ascites that require repeated drainage;
  • Poor control of diabetes (FBG>10 mmol/L);
  • Urine routine indicates urine protein ≥++, and it is confirmed that the 24-hour urine protein quantification is greater than 1.0 g;
  • Have a history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;
  • According to the researcher's judgment, there are accompanying diseases that seriously endanger patient safety or affect patient completion of the study. Unable to understand the nature of the research or disagrees to sign an informed consent form;
  • The researcher evaluates other situations that are not suitable for inclusion in the study.

Quoted from ClinicalTrials.gov, NCT06324994, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06324994, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06324994